<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286089</url>
  </required_header>
  <id_info>
    <org_study_id>CCN_CT02</org_study_id>
    <nct_id>NCT02286089</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration</brief_title>
  <official_title>Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Cure Neurosciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Cure Neurosciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is evaluation of the safety and tolerability of OpRegen -
      human embryonic stem cell-derived retinal pigment epithelial (RPE)cells. The study will also
      include initial exploration of the ability of transplanted OpRegen cells to engraft, survive,
      and moderate disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OpRegenÂ® is a cell-based product composed of retinal pigment epithelial (RPE) cells, derived
      from human embryonic stem cells (hESC) and administered as a cell suspension in ophthalmic
      Balanced Salt Solution Plus (BSS Plus).

      This is a Phase I/IIa, dose-escalation, evaluating safety and tolerability of OpRegen
      transplantation to patients with progressive dry-AMD. The study includes also initial
      exploration of efficacy.

      A total of approximately 24 subjects will be enrolled. The subjects should be 50 years of age
      and older, with non-neovascular (dry) AMD, who have funduscopic findings of GA in the macula,
      with absence of additional concomitant ocular disorders.

      The subjects will be divided into four cohorts, according to their best corrected visual
      acuity (BCVA) and administered OpRegen dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and frequency of treatment emergent adverse events</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>The AE's will be graded using NCI's CTCAE v 3.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent changes of clinical and ophthalmological parameters</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>The parameters will be measured via different modalities, such as vital signs and ocular imaging and captured as adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GA lesion area</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Measurement of change in GA lesion area will be performed based on available imaging data by a central reading center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Change in visual acuity will be measured by ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Change in NEI VFQ-25 Quality of Life score will be measured from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>OpRegen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OpRegen</intervention_name>
    <description>Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space following vitrectomy procedure</description>
    <arm_group_label>OpRegen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 50 and older;

          2. Diagnosis of dry (non-neovascular) age related macular degeneration in both eyes;

          3. Funduscopic findings of dry AMD with progressive geographic atrophy in the macula;

          4. Best corrected central visual acuity equal or less than 20/200 in cohorts 1-3 and
             20/64-20/250 in cohort 4 in the study eye by ETDRS vision testing;

          5. Vision in the non-operated eye must be better than or equal to that in the operated
             eye;

          6. Subjects with sufficiently good health to allow participation in all study-related
             procedures and complete the study follow up period (medical records);

          7. Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care;

          8. Blood counts, blood chemistry, coagulation and urinalysis without abnormal
             significance;

          9. Negative for TB (cohort 4), HIV, HBC, and HCV, negative for CMV IgM and EBV IgM;

         10. Patients with no history of malignancy (other than a non-melanoma skin cancer). For
             cancers in remission for more then 5 years enrollment is allowed with concurred
             documented approval of principal investigator and oncologist prior to enrollment;

         11. Willing to defer all future blood and tissue donation;

         12. Able to understand and willing to sign informed consent.

        Exclusion Criteria:

          1. Evidence of neovascular AMD by history, as well as by clinical exam, fluorescein
             angiography (FA), or ocular coherence tomography (OCT) at baseline in either eye;

          2. History or presence of diabetic retinopathy, vascular occlusions, uveitis, Coat's
             disease, glaucoma, cataract or media opacity preventing posterior pole visualization
             or any significant ocular disease other than AMD that has compromised or could
             compromise vision in the study eye and confound analysis of the primary outcome;

          3. History of retinal detachment repair in the study eye;

          4. Axial myopia greater than -6 diopters;

          5. At least 2 months following cataract removal in the study eye and Yttrium Aluminum
             Garnet (YAG) laser capsulotomy in the study eye in the past 4 weeks and any other
             ocular surgery in the study eye in the past 3 months prior to implantation;

          6. History of cognitive impairments or dementia;

          7. Contraindication for systemic immunosuppression;

          8. History of any condition other than AMD associated with choroidal neovascularization
             in the study eye (e.g. pathologic myopia or presumed ocular histoplasmosis);

          9. Any type of systemic disease or its treatment, in the opinion of the Investigator,
             including any medical condition (controlled or uncontrolled) that could be expected to
             progress, recur, or change to such an extent that it may bias the assessment of the
             clinical status of the patient to a significant degree or put the patient at special
             risk.

         10. Female; pregnancy or breastfeeding;

         11. Current participation in another clinical study. Past participation (within 6 months)
             in any clinical study of a drug administered systemically or to the eye.

         12. Currently receiving aspirin, aspirin containing products and/or any other coagulation
             modifying drugs which cannot be discontinued 7 days prior to surgery;

         13. History of cancer (other than a non-melanoma skin cancer). For cancers cured more than
             five years ago, enrollment is allowed with concurred documented approval of principal
             investigator and oncologist prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gurevich</last_name>
    <role>Study Director</role>
    <affiliation>Cell Cure Neurosciences Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tareq Jaouni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Kerem University Hospital, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rita Ehrlich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haia Morori-Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adiel Barak, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Souraski Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard McDonald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Retina Medical Group, Inc, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Vitreous Associates Medical Group, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Do, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Byers Eye Institute, Stanford, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Telander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retinal Consultants Medical Group, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Gurevich</last_name>
    <phone>+972-733263657</phone>
    <email>maria@cellcure.co.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghesal Razag</last_name>
    <phone>+1 510 8714125</phone>
    <email>grazag@biotimeinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Kurokouchi, B.Sc.</last_name>
      <phone>310-289-2478</phone>
      <phone_ext>1243</phone_ext>
      <email>JKurokouchi@laretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Gerard Aquino, B.Sc.</last_name>
      <phone>310-289-2478</phone>
      <phone_ext>1225</phone_ext>
      <email>GAquino@laretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute, Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Greer, MBA</last_name>
      <phone>650-725-9184</phone>
      <email>lgreer7@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Do, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Nickerman</last_name>
      <phone>916-453-5429</phone>
      <email>nickermane@retinalMD.com</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Lewis</last_name>
      <phone>916-453-5429</phone>
      <email>lewisw@retinalmd.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Telander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin E. Miani, BA</last_name>
      <phone>415-972-4607</phone>
      <email>kmiani@westcoastretina.com</email>
    </contact>
    <contact_backup>
      <last_name>C.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Richard McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devora Marks Ohana</last_name>
      <phone>972-2-6776324</phone>
      <email>dryamdstudy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tareq Jaouni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivi Dagan</last_name>
      <phone>972-3-9377199</phone>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rita Ehrlich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Scwartzberg</last_name>
      <phone>972-8-9441691</phone>
      <email>kaplaneye1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Haia Morori-Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>91121</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagit Bechor</last_name>
      <phone>03-6974361</phone>
      <email>sagitba@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Adiel Barak, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N, Khaner H, Smith Y, Wiser O, Gropp M, Cohen MA, Even-Ram S, Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell. 2009 Oct 2;5(4):396-408. doi: 10.1016/j.stem.2009.07.002.</citation>
    <PMID>19796620</PMID>
  </reference>
  <reference>
    <citation>Tannenbaum SE, Turetsky TT, Singer O, Aizenman E, Kirshberg S, Ilouz N, Gil Y, Berman-Zaken Y, Perlman TS, Geva N, Levy O, Arbell D, Simon A, Ben-Meir A, Shufaro Y, Laufer N, Reubinoff BE. Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications. PLoS One. 2012;7(6):e35325. doi: 10.1371/journal.pone.0035325. Epub 2012 Jun 20.</citation>
    <PMID>22745653</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry-AMD</keyword>
  <keyword>Geographic Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

